Natixis Advisors LLC Grows Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Natixis Advisors LLC lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 76,302 shares of the medical equipment provider’s stock after purchasing an additional 4,920 shares during the period. Natixis Advisors LLC’s holdings in Zimmer Biomet were worth $8,636,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ZBH. North Star Asset Management Inc. raised its stake in Zimmer Biomet by 13.2% during the 1st quarter. North Star Asset Management Inc. now owns 3,580 shares of the medical equipment provider’s stock worth $405,000 after acquiring an additional 417 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its stake in Zimmer Biomet by 17.4% in the first quarter. Mesirow Financial Investment Management Inc. now owns 2,940 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 435 shares during the period. Banque Cantonale Vaudoise acquired a new position in shares of Zimmer Biomet during the first quarter worth about $1,355,000. Federated Hermes Inc. increased its stake in shares of Zimmer Biomet by 26.4% during the first quarter. Federated Hermes Inc. now owns 930 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 194 shares during the period. Finally, Mackenzie Financial Corp increased its stake in shares of Zimmer Biomet by 10.9% during the first quarter. Mackenzie Financial Corp now owns 66,438 shares of the medical equipment provider’s stock worth $7,519,000 after acquiring an additional 6,547 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Sang Yi sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider owned 20,424 shares of the company’s stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.70% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $92.48 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. The company has a market capitalization of $18.30 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 2.12 and a beta of 0.68. The company’s 50 day simple moving average is $93.16 and its 200 day simple moving average is $100.07. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.94 earnings per share. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 21.24%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of recent analyst reports. Evercore ISI dropped their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 8th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. Royal Bank Of Canada decreased their price objective on shares of Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities decreased their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $111.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.